Compare LCTX & CIVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCTX | CIVB |
|---|---|---|
| Founded | 1990 | 1884 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 466.8M |
| IPO Year | 1996 | 2012 |
| Metric | LCTX | CIVB |
|---|---|---|
| Price | $1.49 | $22.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $5.33 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 1.2M | 67.7K |
| Earning Date | 03-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 3.19% |
| EPS Growth | N/A | ★ 31.34 |
| EPS | N/A | ★ 2.64 |
| Revenue | $14,556,000.00 | ★ $19,023,000.00 |
| Revenue This Year | $55.75 | $15.33 |
| Revenue Next Year | $2.96 | $6.44 |
| P/E Ratio | ★ N/A | $8.55 |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $0.37 | $17.47 |
| 52 Week High | $2.09 | $25.59 |
| Indicator | LCTX | CIVB |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 42.97 |
| Support Level | $0.94 | $21.45 |
| Resistance Level | $1.84 | $22.52 |
| Average True Range (ATR) | 0.09 | 0.65 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 15.91 | 37.43 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.